The Technical Analyst
Dermira Inc. [DERM]
Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Dermira Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.95% $3.40
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 67.77 mill |
| EPS: | -0.210 |
| P/E: | -16.19 |
| Earnings Date: | May 20, 2024 |
| SharesOutstanding: | 19.93 mill |
| Avg Daily Volume: | 0.172 mill |
| RATING 2024-04-24 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -16.19 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.34x |
| Company: PE -16.19 | industry: PE 47.78 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.97 - 3.91 ( +/- 13.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-25 | Rosenwald Lindsay A Md | Buy | 10 000 | Common Stock, $0.0001 par value |
| 2024-03-22 | Maraoui Claude | Buy | 10 000 | Common Stock, $0.0001 par value |
| 2024-03-22 | Smith Justin Adam | Buy | 30 000 | Common Stock, $0.0001 par value |
| 2024-03-22 | Rosenwald Lindsay A Md | Buy | 20 000 | Common Stock, $0.0001 par value |
| 2024-02-22 | Benesch Joseph | Sell | 2 450 | Common Stock, $0.0001 par value |
| INSIDER POWER |
|---|
| 75.83 |
| Last 94 transactions |
| Buy: 1 155 250 | Sell: 1 927 470 |
Forecast:
16:00 - $3.44
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.44
Forecast 2: 16:00 - $3.44
Forecast 3: 16:00 - $3.44
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.40 (-3.95% ) |
| Volume | 0.0605 mill |
| Avg. Vol. | 0.172 mill |
| % of Avg. Vol | 35.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DERM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $4.76 | N/A | Active |
|---|
DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Last 10 Buy Signals
Latest Press Releases
2024-03-21 16:01:00 - Press Release
Journey Medical Corporation Reports Full-year 2023 Financial Results And Recent Corporate Highlights
Company generated total revenues of $79.2 million for the full year ended december 31, 2023, a 7% increase from the $73.7 million reported in 2022
2024-03-18 08:30:00 - Press Release
Journey Medical Corporation Announces U.s. Fda Acceptance Of New Drug Application For Dfd-29 For The Treatment Of Rosacea
Prescription drug user fee act (“pdufa”) goal date of november 4, 2024 prescription drug user fee act (“pdufa”) goal date of november 4, 2024
2024-03-15 08:30:00 - Press Release
Journey Medical Corporation To Announce Year End 2023 Financial Results On March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on march 21, 2024 at 4:30 p.m. et company to host conference call to discuss financial results and provide a corporate update on march 21, 2024 at 4:30 p.m. et
2024-03-13 08:30:00 - Press Release
Journey Medical Corporation To Participate In The 36th Annual Roth Conference
Scottsdale, ariz., march 13, 2024 (globe newswire) -- journey medical corporation (“journey medical”) (nasdaq: derm), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of fda-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 36th annual roth conference, which is being held march 17-19, 2024 in dana point, california.
2024-03-11 08:30:00 - Press Release
Journey Medical Corporation Announces Presentation Of Data From Phase 1 Clinical Trial Assessing The Impact Of Dfd-29 (minocycline Hydrochloride Modified Release Capsules, 40 Mg) On Microbial Flora Of Healthy Adults At 2024 Aad Annual Meeting
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues
Latest News
2024-03-21 20:22:02 - Seeking Alpha
Journey Medical Corporation (DERM) Q4 2023 Earning Call Transcript
2024-03-19 09:51:20 - Zacks Investment Research
Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.
2024-03-15 08:30:00 - GlobeNewsWire
Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024
Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 21, 2024 at 4:30 p.m. ET
2023-12-26 10:31:09 - Zacks Investment Research
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
2023-12-20 09:46:04 - Zacks Investment Research
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
2023-12-13 09:47:30 - Zacks Investment Research
Is it a Good Idea to Buy Journey Medical (DERM) Stock Now?
Here, we discuss some reasons why investing in Journey Medical (DERM) stock now may turn out to be a prudent move.
2023-12-11 12:02:11 - Zacks Investment Research
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
2023-12-11 09:01:24 - Zacks Investment Research
Relative Price Strength Makes These 5 Stocks Excellent Buys
2023-12-07 09:47:27 - Zacks Investment Research
4 Growth Stocks to Buy Ahead of a Strong Year-End Rally
With the Fed likely to trim interest rates along with seasonal tailwinds, growth stocks like Beacon Roofing Supply (BECN), TopBuild (BLD), Journey Medical (DERM) and Shift4 Payments (FOUR) are poised to gain strength.
2023-11-30 13:32:31 - Zacks Investment Research
Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great Choice
Does Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out.